Search

Displaying results 931 - 940 of 2815 in total
  1. Drug

    PF-03654746

    go.drugbank.com/drugs/DB12201
    Investigational

    PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.

  2. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    Depemokimab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody and a long-acting drug. Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence. Depemokimab blocks interleukin-5 (IL-5)...

  3. Drug

    Somatotropin

    go.drugbank.com/drugs/DB00052
    ApprovedInvestigational

    [A228188] Recombinant growth hormone is available as a subcutaneous injection for children and adults under a wide variety of brand names.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inducers
  4. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are

  5. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  6. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [A237620] Difelikefalin received FDA approval in August 2021 (under the brand name Korsuva), becoming the first FDA-approved therapy for patients with chronic kidney disease suffering from uremic pruritus

  7. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    [A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto.

  9. Drug

    Pyrethrum extract

    go.drugbank.com/drugs/DB11087
    Approved

    Pyrethrum is the crude extract form obtained from flowers of the plant Chrysanthemum cinerariifolium. Pyrethrin refers to a more refined extract of pyrethrum. While pyrethrum extract is composed of 6 esters, both organic compounds mediat...

    Mixtures: Select Brand Lice Killing, KWELL-P %0,3 + %3 MEDİKAL ŞAMPUAN, 60 ML
  10. Drug

    anti-OX40 antibody BMS 986178

    go.drugbank.com/drugs/DB15773
    Investigational

    A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.